Clinical impact of FDG-PET in patients with suspected recurrent ovarian cancer

Revista Espanola de Medicina Nuclear

Volumn 27, Issue 6, 2008, Pages 411-417

  Cuenca Cuenca, J I ^a   Borrego Dorado, I ^a   Vazquez Albertino R ^a   Gomez Camarero P ^a   Sanz Viedma, S ^a   Fernandez Lopez R ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

Author keywords

Clinical impact; FDG; Ovarian cancer; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; TUMOR MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DIAGNOSTIC AGENT; FLUORINE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PREDICTION AND FORECASTING; PREVALENCE; RADIODIAGNOSIS; RECURRENT CANCER; RETROSPECTIVE STUDY; AGED; BLOOD; CARCINOMA; EVALUATION; LYMPH NODE METASTASIS; METASTASIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVARY TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SPAIN; TUMOR RECURRENCE;

ADULT; AGED; CA-125 ANTIGEN; CA-19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA; COMBINED MODALITY THERAPY; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PREVALENCE; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SPAIN; TUMOR MARKERS, BIOLOGICAL;

EID: 59449084535     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/S1578-200X(08)70043-3     Document Type: Article

References (16)

1. Estrategia en Cáncer del Sistema Nacional de Salud. Ministerio de Sanidad y Consumo. 2006.
2. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 1993;71: 517-23.
3. Cannistra SA. Cancer of the ovary. N Engl J Med. 2004;351:2519-29.
4. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H. Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991;40:103-6.
5. Rustin G, Tuxen M. Use of CA 125 in follow-up of ovarian cancer. Lancet. 1996;348:191-2.
6. Sironi S, Messa C, Mangili G, Zangheri B, Aletti G, Garavaglia E, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004;233:433-40.
7. Zimny M, Siggelkow W, Schröder W, Nowak B, Biemann S, Rath W, et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer. Gynecol Oncol. 2001;83:310-5.
8. Kole A, Nieweg O, Pruim J, Hoekstra H, Koops HS, Roodenburg J, et al. Detection of unknown occult primary tumors using positron emission tomography. Cancer. 1998;82:1160-6.
9. Borrego Dorado I, Gómez Camarero P, Ruiz Franco-Baux J, Vázquez Albertino R. Evaluación de la eficacia y del impacto clínico de la PET-FDG en pacientes con sospecha de recurrencia de cáncer colorrectal. Rev Esp Med Nucl. 2004;23:313-23.
10. Al-Sugair A, Coleman RE. Applications of PET in lung cancer. Semin Nucl Med. 1998;28:303-19.
11. Gadducci A, Cosio S, Zola P, Landoni F, Magginos T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer. 2007;17:21-31.
12. Borrego I, López C, Vázquez R, Ginel A, Barrot E. Evaluación de la eficacia y el impacto clínico de la PET-FDG en los pacientes con carcinoma broncopulmonar no microcítico candidatos a cirugía. Rev Esp Med Nucl. 2007;26:335-44.
13. Franco Baux J, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino R, Navarro González E, et al. PET con 18FDG en pacientes con cáncer diferenciado de tiroides que presentan niveles elevados de tiroglobulina sérica y rastreos con 131-I negativos. Rev Esp Med Nucl. 2005;24:5-13.
14. BOJA. Resolución 18/2001 de la Dirección General del Sistema Andaluz de Salud.
15. Thrall M, DeLoia J, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol Oncol. 2007;105:17-22.
16. Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol Oncol. 2006;103:271-6.